In particular, we caution against the use of rTg4510 for testing potential disease therapies, as we now know that a therapeutic agent could significantly improve or even eliminate tauopathy-like phenotypes in rTg4510 by incidentally correcting effects such as the contributions from the Fgf14 tauP301L-TgINDEL mutation (i.e., as in rT2/T2) without modifying the intended drug target. Here, FGF14 is linked to tauopathy.